Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR., Ewer KJ., Berrie E., Bibi S., Bittaye M., Carroll MW., Flaxman A., Fuskova M., Gorringe A., Hallis B., Kerridge S., Makinson R., Mellors J., Minassian A., Moore M., Mujadidi Y., Rollier CS., Song R., Snape MD., Tarrant R., Watson MEE., Wright D., Douglas AD., Gilbert S., Pollard AJ.

A Correction to this paper has been published: https://doi.org/10.1038/s41591-021-01372-z.

DOI

10.1038/s41591-021-01372-z

Type

Journal article

Journal

Nature medicine

Publisher

Springer Science and Business Media LLC

Publication Date

06/05/2021

Keywords

Oxford COVID Vaccine Trial Group

Permalink Original publication